$GPGI

Composecure (NYSE:GPGI) Trading Up 4.7% After Insider Buying Activity

Composecure (NYSE:GPGI) saw its shares trade up 4.7% after three insiders purchased additional shares in the company on March 17th. Thomas R. Knott, John D. Cote, and Kurt Schoen collectively acquired shares worth over $900,000. Despite this insider buying activity and the stock's rise, Weiss Ratings initiated a "sell" rating, and MarketBeat shows a consensus "Sell" rating for Composecure.

Original reporting
MarketBeat · MarketBeat
Published Mar 18, 2026, 3:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 18, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$GPGI
Neutral
medium confidence
Mentioned
$GPGI
alphai data visualization · based on MarketBeat
Decision brief

The 30-second read

$GPGINeutralMed
01

Why it matters

However, Weiss Ratings has issued a 'sell' rating, indicating potential underlying issues or overvaluation.

02

Market read

The news has moderate relevance for traders focusing on healthcare stocks or short-term trading strategies.

03

What to watch

Potential upcoming negative news or earnings report that could offset insider optimism.

Timing: short-term (next few days)

Background

Composecure (GPGI) has seen recent insider buying activity, which often signals confidence from management.

Company-level read

Ticker impact

$GPGINeutralMedium confidence
Context

The news highlights insider buying activity and a recent stock price increase, which can influence trading decisions.

Expected impact

Potential short-term upward movement, but long-term outlook remains uncertain.

Evidence & confidence

Insider buying suggests confidence, but negative analyst ratings and consensus sell rating temper optimism.

Market effects

Limited sector impact; the company's sector does not show significant movement based on this news.

Minimal regional effects; the news is company-specific.

Negligible

Counterpoint

Despite insider buying, the negative analyst ratings suggest caution; the stock may be overreacting to insider activity.

Key entities

  • Composecure

    A healthcare technology company listed on NYSE.

Related articles

$GPGIMed

GPGI, Inc. (GPGI): Results of Operations and Financial Condition

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gpgi_2q26earningspresent.htm EX-99.2 gpgi_2q26earningspresent Second Quarter 2026 Earnings Presentation August 6, 2026 TM Disclaimer 2 Forward-Looking Statements This presentation, and other statements that GPGI, Inc. (“GPGI,” “we,” “us” or the “Company”) may make in co

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.